Palbociclib is Used for treating HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant. It was first introduced by Pfizer Inc in its drug Ibrance on Feb 3, 2015. 2 different companies have introduced drugs containing Palbociclib.

Palbociclib Patents

Given below is the list of patents protecting Palbociclib, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Ibrance	US11065250	Solid dosage forms of palbociclib	Aug 19, 2036	Pfizer
Ibrance	US10723730	Solid forms of a selective CDK4/6 inhibitor	Feb 08, 2034	Pfizer
Ibrance	USRE47739	2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones	Mar 05, 2027	Pfizer
Ibrance	US6936612	2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones	Jan 16, 2023 (Expired)	Pfizer
Ibrance	US7208489	2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones	Jan 16, 2023 (Expired)	Pfizer
Ibrance	US7456168	2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones	Jan 16, 2023 (Expired)	Pfizer

Add above patents to watchlist

Palbociclib's Family Patents

Full family tree

Palbociclib Generic API Manufacturers

Several generic applications have been filed for Palbociclib.

Given below is the list of companies who have filed for Palbociclib generic, along with the locations of their manufacturing plants worldwide.